Kestra Medical Technologies reports third quarter fiscal 2026 results; raises FY2026 revenue guidance to $93M, representing 55% growth vs. FY2025 by mariel | Mar 17, 2026 | Portfolio News
CytomX Therapeutics reports positive Phase 1 data for CX-2051 (Varseta-M) in colorectal cancer by mariel | Mar 16, 2026 | Portfolio News
AirNexis Therapeutics launches with $200M tranched Series A targeting COPD by mariel | Mar 3, 2026 | Portfolio News
CG Oncology accelerates Phase 3 PIVOT-006 readout to H1 2026 by mariel | Feb 27, 2026 | Portfolio News
FDA grants Priority Review to Vera Therapeutics’ BLA for atacicept in IgA nephropathy; PDUFA date July 7, 2026; completes $800M combined equity and debt financing to support commercial readiness by mariel | Feb 26, 2026 | Portfolio News
OrsoBio reports positive Phase 2a proof-of-concept results for TLC-2716 in hypertriglyceridemia and MASLD by mariel | Feb 10, 2026 | Portfolio News
